ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
About this item
Full title
Author / Creator
Publisher
US: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
US: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Abstract
Objectives
ALK inhibitors (ALKi) are the standard-of-care treatment for metastatic ALK-rearranged non-small cell lung cancer (NSCLC) in the first- and second-line setting. We conducted a real-world multi-institutional analysis, aiming to compare the efficacy of third-line ALKi versus chemotherapy in these patients.
Methods
Cons...
Alternative Titles
Full title
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8842297
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8842297
Other Identifiers
ISSN
1083-7159
E-ISSN
1549-490X
DOI
10.1093/oncolo/oyab005
